View Item 

Show simple item record

The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson’s disease, adds to the complexity of a mutational hotspot
dc.contributor.authorMata, Ignacio F.
dc.contributor.authorDavis, Marie Y.
dc.contributor.authorLopez, Alexis N.
dc.contributor.authorDorschner, Michael O.
dc.contributor.authorMartinez, Erica
dc.contributor.authorYearout, Dora
dc.contributor.authorCholerton, Brenna A.
dc.contributor.authorHu, Shu‐ching
dc.contributor.authorEdwards, Karen L.
dc.contributor.authorBird, Thomas D.
dc.contributor.authorZabetian, Cyrus P.
dc.date.accessioned2016-10-17T21:17:49Z
dc.date.available2017-12-01T21:54:11Zen
dc.date.issued2016-10
dc.identifier.citationMata, Ignacio F.; Davis, Marie Y.; Lopez, Alexis N.; Dorschner, Michael O.; Martinez, Erica; Yearout, Dora; Cholerton, Brenna A.; Hu, Shu‐ching ; Edwards, Karen L.; Bird, Thomas D.; Zabetian, Cyrus P. (2016). "The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson’s disease, adds to the complexity of a mutational hotspot." American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 171(7): 925-930.
dc.identifier.issn1552-4841
dc.identifier.issn1552-485X
dc.identifier.urihttps://hdl.handle.net/2027.42/134134
dc.publisherWiley Periodicals, Inc.
dc.subject.othergenetics
dc.subject.othermovement disorders
dc.subject.otherneuropsychological
dc.titleThe discovery of LRRK2 p.R1441S, a novel mutation for Parkinson’s disease, adds to the complexity of a mutational hotspot
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMedicine (General)
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134134/1/ajmgb32452.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/134134/2/ajmgb32452_am.pdf
dc.identifier.doi10.1002/ajmg.b.32452
dc.identifier.sourceAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics
dc.identifier.citedreferenceSimonâ Sanchez J, Martiâ Masso JF, Sanchezâ Mut JV, Paisanâ Ruiz C, Martinezâ Gil A, Ruizâ Martinez J, Saenz A, Singleton AB, Lopez de Munain A, Perezâ Tur J. 2006. Parkinson’s disease due to the R1441G mutation in Dardarin: A founder effect in the Basques. Mov Disord 21 ( 11 ): 1954 â 1959.
dc.identifier.citedreferenceKitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 ( 6676 ): 605 â 608.
dc.identifier.citedreferenceLiao J, Wu CX, Burlak C, Zhang S, Sahm H, Wang M, Zhang ZY, Vogel KW, Federici M, Riddle SM, Nichols RJ, Liu D, Cookson MR, Stone TA, Hoang QQ. 2014. Parkinson diseaseâ associated mutation R1441H in LRRK2 prolongs the â active stateâ of its GTPase domain. Proc Natl Acad Sci USA 111 ( 11 ): 4055 â 4060.
dc.identifier.citedreferenceMata IF, Cosentino C, Marca V, Torres L, Mazzetti P, Ortega O, Raggio V, Aljanati R, Buzo R, Yearout D, Dieguez E, Zabetian CP. 2009a. LRRK2 mutations in patients with Parkinson’s disease from Peru and Uruguay. Parkinsonism Relat Disord 15 ( 5 ): 370 â 373.
dc.identifier.citedreferenceMata IF, Hutter CM, Gonzalezâ Fernandez MC, de Pancorbo MM, Lezcano E, Huerta C, Blazquez M, Ribacoba R, Guisasola LM, Salvador C, Gomezâ Esteban JC, Zarranz JJ, Infante J, Jankovic J, Deng H, Edwards KL, Alvarez V, Zabetian CP. 2009b. Lrrk2 R1441Gâ related Parkinson’s disease: Evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics 10 ( 4 ): 347 â 353.
dc.identifier.citedreferenceMata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, Shprecher DR, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Incaâ Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian CP. 2015. The RAB39B p.G192R mutation causes Xâ linked dominant Parkinson’s disease. Mol Neurodegener 10 ( 1 ): 50.
dc.identifier.citedreferenceMuslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ, Group CS. 2008. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 70 ( 23 ): 2241 â 2247.
dc.identifier.citedreferenceNuytemans K, Rademakers R, Theuns J, Pals P, Engelborghs S, Pickut B, de Pooter T, Peeters K, Mattheijssens M, Van den Broeck M, Cras P, De Deyn PP, van Broeckhoven C. 2008. Founder mutation p.R1441C in the leucineâ rich repeat kinase 2 gene in Belgian Parkinson’s disease patients. Eur J Hum Genet 16 ( 4 ): 471 â 479.
dc.identifier.citedreferencePaisanâ Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, de Munain AL, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Martiâ Masso JF, Perezâ Tur J, Wood NW, Singleton AB. 2004. Cloning of the gene containing mutations that cause PARK8â linked Parkinson’s disease. Neuron 44 ( 4 ): 595 â 600.
dc.identifier.citedreferencePaisanâ Ruiz C, Lewis PA, Singleton AB. 2013. LRRK2: Cause, risk, and mechanism. J Parkinsons Dis 3 ( 2 ): 85 â 103.
dc.identifier.citedreferencePaisanâ Ruiz C, Saenz A, Lopez de Munain A, Marti I, Martinez Gil A, Martiâ Masso JF, Perezâ Tur J. 2005. Familial Parkinson’s disease: Clinical and genetic analysis of four Basque families. Ann Neurol 57 ( 3 ): 365 â 372.
dc.identifier.citedreferencePolymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alphaâ synuclein gene identified in families with Parkinson’s disease. Science 276 ( 5321 ): 2045 â 2047.
dc.identifier.citedreferenceRoss OA, Spanaki C, Griffith A, Lin CH, Kachergus J, Haugarvoll K, Latsoudis H, Plaitakis A, Ferreira JJ, Sampaio C, Bonifati V, Wu RM, Zabetian CP, Farrer MJ. 2009. Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism Relat Disord 15 ( 6 ): 466 â 467.
dc.identifier.citedreferenceRuizâ Martinez J, Gorostidi A, Ibanez B, Alzualde A, Otaegui D, Moreno F, Lopez de Munain A, Bergareche A, Gomezâ Esteban JC, Marti Masso JF. 2010. Penetrance in Parkinson’s disease related to the LRRK2 R1441G mutation in the Basque country (Spain). Mov Disord 25 ( 14 ): 2340 â 2345.
dc.identifier.citedreferenceSmith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. 2006. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9 ( 10 ): 1231 â 1233.
dc.identifier.citedreferenceSomme JH, Molano Salazar A, Gonzalez A, Tijero B, Berganzo K, Lezcano E, Fernandez Martinez M, Zarranz JJ, Gomezâ Esteban JC. 2015. Cognitive and behavioral symptoms in Parkinson’s disease patients with the G and R1441G mutations of the LRRK2 gene. Parkinsonism Relat Disord 21 ( 5 ): 494 â 499.
dc.identifier.citedreferenceSrivatsal S, Cholerton B, Leverenz JB, Wszolek ZK, Uitti RJ, Dickson DW, Weintraub D, Trojanowski JQ, Van Deerlin VM, Quinn JF, Chung KA, Peterson AL, Factor SA, Woodâ Siverio C, Goldman JG, Stebbins GT, Bernard B, Ritz B, Rausch R, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Mata IF, Hu SC, Montine KS, Johnson C, Montine TJ, Edwards KL, Zhang J, Zabetian CP. 2015. Cognitive profile of LRRK2â related Parkinson’s disease. Mov Disord 30 ( 5 ): 728 â 733.
dc.identifier.citedreferenceValente EM, Abouâ Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, Gonzalezâ Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. 2004. Hereditary earlyâ onset Parkinson’s disease caused by mutations in PINK1. Science 304 ( 5674 ): 1158 â 1160.
dc.identifier.citedreferenceVilarinoâ Guell C, Rajput A, Milnerwood AJ, Shah B, Szuâ Tu C, Trinh J, Yu I, Encarnacion M, Munsie LN, Tapia L, Gustavsson EK, Chou P, Tatarnikov I, Evans DM, Pishotta FT, Volta M, Beccanoâ Kelly D, Thompson C, Lin MK, Sherman HE, Han HJ, Guenther BL, Wasserman WW, Bernard V, Ross CJ, Appelâ Cresswell S, Stoessl AJ, Robinson CA, Dickson DW, Ross OA, Wszolek ZK, Aasly JO, Wu RM, Hentati F, Gibson RA, McPherson PS, Girard M, Rajput M, Rajput AH, Farrer MJ. 2014. DNAJC13 mutations in Parkinson disease. Hum Mol Genet 23 ( 7 ): 1794 â 1801.
dc.identifier.citedreferenceVilarinoâ Guell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, Sotoâ Ortolaza AI, Cobb SA, Wilhoite GJ, Bacon JA, Behrouz B, Melrose HL, Hentati E, Puschmann A, Evans DM, Conibear E, Wasserman WW, Aasly JO, Burkhard PR, Djaldetti R, Ghika J, Hentati F, Krygowskaâ Wajs A, Lynch T, Melamed E, Rajput A, Rajput AH, Solida A, Wu RM, Uitti RJ, Wszolek ZK, Vingerhoets F, Farrer MJ. 2011. VPS35 mutations in Parkinson disease. Am J Hum Genet 89 ( 1 ): 162 â 167.
dc.identifier.citedreferenceWalser JC, Furano AV. 2010. The mutational spectrum of nonâ CpG DNA varies with CpG content. Genome Res 20 ( 7 ): 875 â 882.
dc.identifier.citedreferenceYescas P, Lopez M, Monroy N, Boll MC, Rodriguezâ Violante M, Rodriguez U, Ochoa A, Alonso ME. 2010. Low frequency of common LRRK2 mutations in Mexican patients with Parkinson’s disease. Neurosci Lett 485 ( 2 ): 79 â 82.
dc.identifier.citedreferenceZabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, Raskind WH, Griffith A. 2005. A clinicâ based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65 ( 5 ): 741 â 744.
dc.identifier.citedreferenceZabetian CP, Yamamoto M, Lopez AN, Ujike H, Mata IF, Izumi Y, Kaji R, Maruyama H, Morino H, Oda M, Hutter CM, Edwards KL, Schellenberg GD, Tsuang DW, Yearout D, Larson EB, Kawakami H. 2009. LRRK2 mutations and risk variants in Japanese patients with Parkinson’s disease. Mov Disord 24 ( 7 ): 1034 â 1041.
dc.identifier.citedreferenceZimprich A, Benetâ Pages A, Struhal W, Graf E, Eck SH, Offman MN, Haubenberger D, Spielberger S, Schulte EC, Lichtner P, Rossle SC, Klopp N, Wolf E, Seppi K, Pirker W, Presslauer S, Mollenhauer B, Katzenschlager R, Foki T, Hotzy C, Reinthaler E, Harutyunyan A, Kralovics R, Peters A, Zimprich F, Brucke T, Poewe W, Auff E, Trenkwalder C, Rost B, Ransmayr G, Winkelmann J, Meitinger T, Strom TM. 2011. A mutation in VPS35, encoding a subunit of the retromer complex, causes lateâ onset Parkinson disease. Am J Hum Genet 89 ( 1 ): 168 â 175.
dc.identifier.citedreferenceZimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Mullerâ Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. 2004. Mutations in LRRK2 cause autosomalâ dominant parkinsonism with pleomorphic pathology. Neuron 44 ( 4 ): 601 â 607.
dc.identifier.citedreferenceAarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G, Norwegian ParkWest Study G. 2009. Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest study. Neurology 72 ( 13 ): 1121 â 1126.
dc.identifier.citedreferenceAlcalay RN, Mejiaâ Santana H, Mirelman A, Saundersâ Pullman R, Raymond D, Palmese C, Caccappolo E, Ozelius L, Orrâ Urtreger A, Clark L, Giladi N, Bressman S, Marder K, Consortium LAJ. 2015. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson’s disease. Parkinsonism Relat Disord 21 ( 2 ): 106 â 110.
dc.identifier.citedreferenceBonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, Dekker MC, Squitieri F, Ibanez P, Joosse M, van Dongen JW, Vanacore N, van Swieten JC, Brice A, Meco G, van Duijn CM, Oostra BA, Heutink P. 2003. Mutations in the DJâ 1 gene associated with autosomal recessive earlyâ onset parkinsonism. Science 299 ( 5604 ): 256 â 259.
dc.identifier.citedreferenceCholerton BA, Zabetian CP, Quinn JF, Chung KA, Peterson A, Espay AJ, Revilla FJ, Devoto J, Watson GS, Hu SC, Edwards KL, Montine TJ, Leverenz JB. 2013. Pacific Northwest Udall Center of excellence clinical consortium: Study design and baseline cohort characteristics. J Parkinsons Dis 3 ( 2 ): 205 â 214.
dc.identifier.citedreferenceCingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. 2012. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; isoâ 2; isoâ 3. Fly (Austin) 6 ( 2 ): 80 â 92.
dc.identifier.citedreferenceCornejoâ Olivas MR, Torres L, Mata IF, Mazzetti P, Rivas D, Cosentino C, Incaâ Martinez M, Cuba JM, Zabetian CP, Leverenz JB. 2015. A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics. Parkinsonism Relat Disord 21 ( 5 ): 444 â 448.
dc.identifier.citedreferenceCoulondre C, Miller JH, Farabaugh PJ, Gilbert W. 1978. Molecular basis of base substitution hotspots in Escherichia coli. Nature 274 ( 5673 ): 775 â 780.
dc.identifier.citedreferenceCriscuolo C, De Rosa A, Guacci A, Simons EJ, Breedveld GJ, Peluso S, Volpe G, Filla A, Oostra BA, Bonifati V, De Michele G. 2011. The LRRK2 R1441C mutation is more frequent than G2019S in Parkinson’s disease patients from southern Italy. Mov Disord 26 ( 9 ): 1733 â 1736.
dc.identifier.citedreferenceEhrlich M, Wang RY. 1981. 5â Methylcytosine in eukaryotic DNA. Science 212 ( 4501 ): 1350 â 1357.
dc.identifier.citedreferenceEstanga A, Rodriguezâ Oroz MC, Ruizâ Martinez J, Barandiaran M, Gorostidi A, Bergareche A, Mondragon E, Lopez de Munain A, Martiâ Masso JF. 2014. Cognitive dysfunction in Parkinson’s disease related to the R1441G mutation in LRRK2. Parkinsonism Relat Disord 20 ( 10 ): 1097 â 1100.
dc.identifier.citedreferenceGorostidi A, Ruizâ Martinez J, Lopez de Munain A, Alzualde A, Marti Masso JF. 2009. LRRK2 G and R1441G mutations associated with Parkinson’s disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 10 ( 2 ): 157 â 159.
dc.identifier.citedreferenceGuo L, Gandhi PN, Wang W, Petersen RB, Wilsonâ Delfosse AL, Chen SG. 2007. The Parkinson’s diseaseâ associated protein, leucineâ rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313 ( 16 ): 3658 â 3670.
dc.identifier.citedreferenceHatano T, Funayama M, Kubo S, Mata IF, Oji Y, Mori A, Zabetian CP, Waldherr SM, Yoshino H, Oyama G, Shimo Y, Fujimoto K, Oshima H, Kunii Y, Yabe H, Mizuno Y, Hattori N. 2014. Identification of a Japanese family with LRRK2 p.R1441Gâ related Parkinson’s disease. Neurobiol Aging 35 ( 11 ): 2656; e17â 23.
dc.identifier.citedreferenceHaugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, De Deyn PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V, Van Broeckhoven C, Farrer MJ, Wszolek ZK. 2008. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology 70 ( 16 Pt 2 ): 1456 â 1460.
dc.identifier.citedreferenceHaugarvoll K, Wszolek ZK. 2009. Clinical features of LRRK2 parkinsonism. Parkinsonism Relat Disord 15 ( Suppl 3 ): S205 â S208.
dc.identifier.citedreferenceHealy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW. 2008. Phenotype, genotype, and worldwide genetic penetrance of LRRK2â associated Parkinson’s disease: A caseâ control study. Lancet Neurol 7 ( 7 ): 583 â 590.
dc.identifier.citedreferenceHwang DG, Green P. 2004. Bayesian Markov chain Monte Carlo sequence analysis reveals varying neutral substitution patterns in mammalian evolution. Proc Natl Acad Sci USA 101 ( 39 ): 13994 â 14001.
dc.identifier.citedreferenceKircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. 2014. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46 ( 3 ): 310 â 315.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ajmgb32452.pdf
Size:
223.4KB
Format:
PDF
View/Open
Name:
ajmgb32452_am.pdf
Size:
172.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.